Breadcrumb
- Home
- Publications
- Proceedings
- 2009 Annual Meeting
- Food, Pharmaceutical & Bioengineering Division
- Poster Session: Engineering Fundamentals in Life Science
- (489q) Delivery of Cyclosporin A by Puncta Plugs for the Treatment of Dry Eyes
Our design for puncta plugs includes a cyclosporin A containing HEMA (Hydroxy Ethyl Methacrylate) core, with a fraction of the length coated by a silicon shell. These plugs have a core diameter of 0.53 mm and a plug diameter of 0.93mm, have an exposed length of 2mm and an overall length of 3mm. The plugs will be inserted with the coated side towards the nose so that drug can diffuse radially outwards from the uncoated section and then diffuse axially through the tears into the eyes. The ratio of exposed to unexposed length can be adjusted to suit the therapeutic requirement.
Plugs have been successfully prepared that have a zero order release of cyclosporin A for a period of 40 days at a rate of about 4 µg/day. Several in vitro experiments have been conducted to study the effect of drug concentration in the core, effect of crosslinking in the core and the effect of ratio of exposed to unexposed part on drug release. Also, the plugs do not have any initial burst of drug; therefore there would be no problem of over dosage while using these plugs.
Puncta plugs are made of bio-compatible materials and can release cyclosporin A for a period of more than 40 days at a therapeutic rate. The rate of release can be controlled by varying the crosslinking or the drug loading in the core. The plugs developed can also be used to deliver different drugs for other diseases apart from dry eyes.